Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of Nov. 7, 2011. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.CAREFUSION CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF INCOME(UNAUDITED)Quarter Ended September 30,(in millions, except per share amounts)20112010Revenue

$

844

$

811Cost of Products Sold417398Gross Margin427413Selling, General and Administrative Expenses273272Research and Development Expenses3940Restructuring and Acquisition Integration Charges722Operating Income10879Interest Expense and Other, Net 2523Income Before Income Tax8356Provision for Income Tax1620Income from Continuing Operations6736Income from Discontinued Operations, Net of Tax-2Net Income

$

67

$

38Per Share Amounts:(1)Basic Earnings per Common Share:Continuing Operations

$

0.30

$

0.17Discontinued Operations

$

-

$

0.01Basic Earnings per Common Share

$

0.30

$

0.17Diluted Earnings per Common Share:Continuing Operations

$

0.30

$

0.17Discontinued Operations

$

-

$

0.01Diluted Earnings per Common Share

$

0.30

$

0.17Weighted-Average Number of Common Shares Outstanding:Basic223.8222.1Diluted226.3223.9____________1Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from th
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... http://www.draperuniversity.com , is proud to announce that ... from 17 different countries will converge on the ... Valley for an intensive, experiential program focused on ... The highly selective school, currently running its sixth ...
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
(Date:7/23/2014)... Al Khaimah, United Arab Emirates (UAE) (PRWEB) July 23, ... firm Grace Century recently announced that its ... Dr. Jim Vaught , Ph.D. to its growing Advisory ... said, “We are very pleased to have Dr. Vaught ... with the scientific depth and expertise that Provia’s management ...
(Date:7/23/2014)... Physicists Sergei Filippov (MIPT and Russian Quantum Center ... Brno, Czech Republic, and the Institute of Physics ... preserve quantum entanglement of particles passing through an ... long distances. Details are provided in an article ... (see preprint). , Quantum entangled particles are ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4
... enhances Microsoft Amalga Life Sciences to accelerate basic research ... June 1 Microsoft Corp. today announced that it ... to acquire certain assets of Rosetta Biosoftware, a business ... of Merck & Co. Inc. The deal allows Microsoft ...
... Move strengthens Kendle,s position as a global clinical ... , CINCINNATI, June 1 Kendle (Nasdaq: ... research organization, today announced the opening of offices ... Philippines. The new operations provide Kendle,s global ...
... , ADHD symptom control demonstrated from the first time ... , PHILADELPHIA, June 1 Shire ... global specialty biopharmaceutical company, today announced that the US ... to the prescribing information for its once-daily Attention Deficit ...
Cached Biology Technology:Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 2Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 3Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila 2Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 2FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 4FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 5FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 6FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 7
(Date:7/24/2014)... soup in which life arose have been maintained in our ... Anglia. , Research published today in the Journal of ... very likely also in animals still perform ancient reactions thought ... some four billion years ago. , The primordial soup theory ... a result of the combination of metals, gases from the ...
(Date:7/24/2014)... in German . ... asthma sufferers worldwide, a further 600 million people living ... global population contending with allergic rhinitis (allergic inflammation of ... other organs and parts of the body beyond the ... the form of inflammatory bowel diseases such as colitis ...
(Date:7/24/2014)... doctors and scientists from Singapore have developed Asia,s first ... eye disease that affects the cornea called corneal stromal ... vision. , Called the POLARIS TGFBI (Transforming Growth ... to aid in the diagnosis and management of patients ... members carrying a TGFBI mutation who may also be ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Singapore team develops Asia's first genetic test that can prevent corneal blindness 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 3
... leaf has revealed the oldest known evidence of a macabre ... to turn them into zombies. The discovery has been ... Hughes, from the University of Exeter, who studies parasites that ... manner of animals are susceptible to the often deadly body ...
... from Mount Sinai School of Medicine have enhanced our ... conversion, the process in which food is converted into ... scientists gain atomic-level insight into how organisms synthesize their ... published in the August issue of PLoS Biology ...
... Mont. -- Researchers at Montana State University have ... for treating antibiotic resistant infections, fungal infections and viral ... to study such compounds. The technologies are ... The first technology involves an existing clinical drug ...
Cached Biology News:Fossil reveals 48-million-year history of zombie ants 2Mount Sinai researchers discover new mechanism behind cellular energy conversion 2Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4
delta-like 1 homolog (Drosophila)...
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
SHEEP ANTI ECHIS OCCELATUS (VENOM)...
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Biology Products: